Gilead’s ADC Medicine Falls Short of Target in Highly Monitored Lung Cancer Study Gilead Sciences, a leading biopharmaceutical company, recently...
Title: Promising Results: First Patient in Phase 1 Clinical Trial of PMB-CT01 Achieves Complete Remission for Relapsed and Refractory B-cell...
The Importance of Mettl3-dependent m6A Modification in Effector Differentiation Effector differentiation is a crucial process in the immune system that...
LegoChem Biosciences, a leading biopharmaceutical company based in South Korea, has recently announced a licensing deal with Janssen Pharmaceuticals, a...
Understanding the Challenges and Increasing Popularity of Antibody-Drug Conjugates Antibody-drug conjugates (ADCs) have emerged as a promising class of targeted...
Sanofi, one of the world’s leading pharmaceutical companies, recently announced the discontinuation of the development of tusamitamab ravtansine, a potential...
CaONPs: A Dual-Function Substance for Cancer Treatment and Microbial Resistance In recent years, the field of nanotechnology has shown great...
GSK Expands ADC Dealings by Establishing Second Biotech Partnership in China GlaxoSmithKline (GSK), a leading global pharmaceutical company, has recently...
Pfizer, one of the world’s leading pharmaceutical companies, has recently announced a collaboration with Nona, a biotechnology company specializing in...
Manganese Nanoadjuvant Formulated Subunit Vaccine: Promoting Long-lasting and Strengthened Immunity against SARS-CoV-2 The ongoing COVID-19 pandemic caused by the severe...
In the world of pharmaceuticals and medical research, there are always exciting developments and breakthroughs that capture the attention of...
Bristol Myers Squibb, a leading global biopharmaceutical company, recently announced its acquisition of SystImmune for a whopping $800 million. This...
Scientific Reports: Investigating the Powerful Antimicrobial and Anti-Lung Cancer Effects of Bacterial Polysaccharide Coated with Selenium Nanoparticles In recent years,...
A Promising Treatment Option for Small Cell Lung Cancer Patients Who Have Undergone Prior Treatment: Tarlatamab Small cell lung cancer...
AbbVie, a global biopharmaceutical company, has recently announced its acquisition of Immunogen, a leading manufacturer of targeted cancer medications, in...
